Valuation: Hemogenyx Pharmaceuticals Plc

Market Cap 45.56M 59.62M 54.33M 50.06M 85.5M 5.52B 90.1M 610M 242M 3.01B 223M 219M 9.45B P/E 2024
-2.38x
P/E 2025 -2.6x
Enterprise Value 45.98M 60.16M 54.83M 50.52M 86.28M 5.57B 90.92M 615M 244M 3.04B 225M 221M 9.54B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
70.98%
Yield 2024 *
-
Yield 2025 -
1 day-2.97%
1 week+7.37%
Current month+18.37%
1 month-3.60%
3 months+8.41%
6 months-1.11%
Current year+17.13%
1 week 621
Extreme 621
730
1 month 521
Extreme 521
750
Current year 430
Extreme 430
1,220
1 year 356
Extreme 356
1,220
3 years 124
Extreme 124
2,853.6
5 years 124
Extreme 124
2,853.6
10 years 124
Extreme 124
6,155
Manager TitleAgeSince
Chief Executive Officer 61 04/10/2017
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 04/10/2017
Director/Board Member - 04/10/2017
Director/Board Member 78 04/10/2017
Date Insider Type Main position Quantity % Market Cap. Importance
5/29/26 A Free

Director

300,000 4.4118%
5/29/26 A Free

Founder

300,000 4.4118%
5/29/26 A Free

Founder

300,000 4.4118%
Change 5-day change 1-year change 3-year change Capi.($)
-2.97%+7.37%-23.86%-33.00% 61.55M
-2.49%-6.35%+51.07%+64.95% 65.42B
-0.63%-3.81%+6.95%+88.55% 58.91B
-2.37%-2.22%+22.96%+83.44% 55.24B
-2.19%-6.02%+10.50%+109.19% 45.66B
-1.89%-9.33%+13.03%+20.04% 41.29B
-0.93%+1.67%+20.83%+45.03% 36.82B
+1.11%-8.59%+128.56%+655.74% 34.48B
-0.80%-1.73%+75.29%+56.47% 32.5B
-2.17%+19.70%-30.57%+469.42% 31.69B
Average -1.53%+0.48%+27.48%+155.98% 40B
Weighted average by Cap. -1.49%-1.28%+31.62%+151.38%

Financials

2024 2025
Net sales - -
Net income -5.62M -7.35M -6.7M -6.17M -10.54M -681M -11.11M -75.22M -29.8M -371M -27.54M -27M -1.17B -9.76M -12.77M -11.64M -10.72M -18.32M -1.18B -19.3M -131M -51.76M -645M -47.84M -46.91M -2.03B
Net Debt 2.46M 3.22M 2.94M 2.71M 4.62M 299M 4.87M 32.98M 13.07M 163M 12.08M 11.84M 511M 418K 547K 498K 459K 784K 50.62M 826K 5.59M 2.22M 27.61M 2.05M 2.01M 86.69M
Projected Income Statement - Annual - Hemogenyx Pharmaceuticals Plc
Logo Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals plc is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of a suite of products to address problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, and viral infections. Its products include immunotherapy product candidates for the treatment of acute myeloid leukemia (AML) and other blood malignancies and patient conditioning for bone marrow transplantation (the CDX bi-specific antibody and CAR-T therapy), and a cell therapy product for BM/HSC transplantation (the Hu-PHEC). Its lead product, HG-CT-1, is a CAR-T cell therapy designed to treat relapsed or refractory acute myeloid leukemia (R/R AML), which is in a Phase I clinical trial. Its Chimeric Bait Receptor (CBR) is a versatile range of potential treatments based on the methodology of programming immune cells using a type of modifiable synthetic receptor to destroy viral pathogens.
Employees
16
Date Price Change Volume
20/11/26 GBX 670.00 -2.97% 6,391
19/11/26 GBX 690.50 +3.06% 4,736
18/11/26 GBX 670.00 -1.54% 2,689
17/11/26 GBX 680.50 -4.15% 1,774
16/11/26 GBX 710.00 +4.41% 7,381
  1. Stock Market
  2. Stocks
  3. SILF Stock